CJC-1295 + Ipamorelin vs IGF-1
CJC-1295 + Ipamorelin and IGF-1 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 + Ipamorelin is combination — ghrh(1-29) analogue plus selective ghrelin-receptor agonist, while IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus dilute acetic acid for initial dissolution); their leading degradation routes differ (independent degradation of the two components at different rates, which is the defining stability characteristic of any blend. for CJC-1295 + Ipamorelin, misfolding and irreversible denaturation for IGF-1), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 + Ipamorelin — origin
This is a two-compound blend studied for complementary mechanisms rather than a single molecule. CJC-1295 is a modified GHRH(1-29) fragment with four amino-acid substitutions that resist enzymatic degradation. Ipamorelin is a pentapeptide ghrelin-receptor agonist notable for its selectivity — it was specifically developed to stimulate GH release without the cortisol and prolactin effects of earlier secretagogues like GHRP-6.
IGF-1 — origin
IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.
CJC-1295 + Ipamorelin research themes
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
IGF-1 research themes
Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.
Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.
Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.
CJC-1295 + Ipamorelin handling
- Confirm whether the labelled mass is total blend mass or per-component before calculating concentration.
- Reconstitute the full vial rather than attempting to subdivide dry material — the two components will not partition evenly in powder form.
- Protect from light and refrigerate.
IGF-1 handling
- Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
- Use a carrier protein and low-bind labware to prevent adsorptive loss.
- Aliquot for single use; do not re-freeze reconstituted protein.
Both third-party tested
Every Popular Peptides batch of CJC-1295 + Ipamorelin and IGF-1 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 + Ipamorelin reference
Related comparisons
CJC-1295 + Ipamorelin and IGF-1 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.